The research and development of smart radiodrugs is the goal of the Center of Radiopharmaceutical Science of ETH, PSI, and USZ. Positron Emission Tomography (PET) allows the non-invasive visualization of biochemical processes within the body. Radiolabeled PET-tracers allow the study
of neurophysiological diseases like Alzheimer, Parkinson's disease or the imaging of metastatic tumors. PET-techniques are nowadays an important part of routine nuclear medicine diagnosis. Tumor-cell targeting biomolecules (e.g. antibodies or peptides) coupled to therapeutic radionuclides
can sterilize the malignant cells while sparing healthy tissue. This so-called targeted radionuclide therapy has made tremendous progress in the recent years and the first approved radiotherapeutics are available for clinical use.
No Supplementary Data.
No Article Media
Document Type: Research Article
October 1, 2004
More about this publication?
International Journal for Chemistry and Official Membership Journal of the Swiss Chemical Society (SCS) and its Divisions
CHIMIA, a scientific journal for chemistry in the broadest sense, is published 10 times a year and covers the interests of a wide and diverse readership. Contributions from all fields of chemistry and related areas are considered for publication in the form of Review Articles and Notes. A characteristic feature of CHIMIA are the thematic issues, each devoted to an area of great current significance.
- Editorial Board
- Information for Authors
- Subscribe to this Title
- Information for Advertisers
- Ingenta Connect is not responsible for the content or availability of external websites